Maxigesic IV(R) registered in the UK and Ireland

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969





19 October 2021
Maxigesic IV® registered in the UK and Ireland
National registration licenses granted for the intravenous form of Maxigesic in both
the UK and Ireland as the easing of COVID-19 restrictions support growth
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces the intravenous form of
its patented pain relief medicine, Maxigesic IV, has now gained regulatory approval
in both the UK and Ireland.
Edge Pharmaceuticals, the licensee for the UK and Jed Pharma, the licensee in
Ireland, are now gearing up to commence sales in the first quarter of the 2022
calendar year.
The approvals bring the number of countries in which AFT Pharmaceuticals has
obtained regulatory approval for Maxigesic IV to 27 from 21 countries at the end of
March 2021. They also demonstrate the continuing progress AFT is making
commercialising is intellectual property in the face of COVID-19 disruptions.
AFT Managing Director Dr Hartley Atkinson said: “More than 3.1million surgical
procedures are performed in these markets each year. Maxigesic IV represents an
effective non-opioid alternative for the management of mild to moderate pain for
many of these cases.
“Demand is also expected to remain strong with the UK and Irish postoperative pain
markets growing at a compound annual rate of 13.2% and forecast to reach US$122
million by 2028.
1

Dr Atkinson said the launch of Maxigesic IV in the UK and Ireland was opportune.
“We believe the market environment in Ireland and the UK is positive for a launch with
hospitals - the primary users of Maxigesic IV - now catching up on a backlog of
elective surgical procedures that have built up over the pandemic.
Dr Atkinson also said the easing of COVID-19 restrictions in NSW last week and Victoria
following suit this week suggested a supportive trading outlook for Australia, AFT’s
largest business unit.
“We are pleased to see these positive steps in Australia, where we are preparing for
over ten new product launches across our eyecare, dermatology, hospital injectable,
medicated vitamins and pain therapeutic areas in the next six months. We look

1
Postoperative Pain Market Insights, Epidemiology and Market Forecast – 2028 - DelveInsight

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969

forward to providing further detail when we release our half-year financial result in
mid-November.”
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO
For more information:
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over-the-counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded and generic drugs. Our business model is to develop and in-license products
for sale by our own dedicated sales teams in our home markets of Australia and New
Zealand and in certain Southeast Asian markets, and to out-license our products to
local licensees and distributors to the rest of the world. For more information:
aftpharm.com
About Maxigesic IV®
Maxigesic IV has been developed under the development collaboration agreement
signed in 2012 between AFT Pharmaceuticals and Hyloris. Maxigesic IV is a unique
combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion for
use post-operatively.
Results from a randomised, double-blind, placebo-controlled Phase 3 trial in 276
patients following bunion surgery demonstrated that Maxigesic IV was well-tolerated
and had a faster onset of action and offered higher pain relief compared to ibuprofen
IV or paracetamol IV alone in the same doses.
Moreover, the superior analgesic effect of Maxigesic IV was supported by a range of
secondary endpoints, including reduced opioid consumption compared to the
paracetamol IV and ibuprofen IV treatment groups